Leveraging its integrated AI + chemical genomics technology platform, the Company focuses its R&D pipeline on two major therapeutic areas—oncology and metabolic diseases—while also exploring areas with significant unmet clinical needs, including neurodegenerative and autoimmune diseases.The Company has built a pipeline of candidate programs with first-in-class or best-in-class potential, several of which have advanced into clinical development. These programs and products are expected to become important drivers of the Company's future growth and value.